日前，葛兰素史克中国投资有限公司四名高管，因涉嫌严重经济犯罪，被警方以涉嫌“商业贿赂和涉税犯罪”采取刑事强制措施。7月15日，葛兰素史克公司在官网发出致歉声明。
以下为致歉声明全文：
我们对本公司某些员工及第三方机构因欺诈和不道德行为所面临的严重指控，深表关切与失望。上述行为严重违背了葛兰素史克全球的规章制度、管理流程、价值观和标准。葛兰素史克对此类行为绝不姑息和容忍。
葛兰素史克支持中国政府根除腐败的决心。上述调查中所发现的问题令人羞愧，我们对所发生的事情深表歉意。
我们将全力配合相关政府部门对最新披露的情况的调查。我们将根据调查所做出的结论，采取一切必要的行动。
同时，我们也正采取一系列紧急措施。我们正重新审查与所有第三方代理的合作，并已立即停止使用本次调查所涉旅行社的服务，同时全面检查所有与旅行社相关的历史合作记录。我们还将认真审查我们在中国的合规工作流程。
葛兰素史克高度重视中国的法律法规，并要求所有员工严格遵守。
葛兰素史克全力支持中国政府的医疗改革，并愿随时与相关部门合作，为使中国患者得到更好的救治做出自已的努力。
We are deeply concerned and disappointed by these serious allegations of fraudulent behaviour and ethical misconduct by certain individuals at the company and third-party agencies. Such behaviour would be a clear breach of GSKs systems，governance procedures，values and standards. GSK has zero tolerance for any behaviour of this nature.
GSK shares the desire of the Chinese authorities to root out corruption. These allegations are shameful and we regret this has occurred.
We will cooperate fully with the Chinese authorities in the investigation of these new allegations. We will take all necessary action required by the outcome of this investigation.
In the meantime，we are taking a number of immediate actions. We are reviewing all third party agency relationships. We have put an immediate stop on the use of travel agencies that have been identified so far in this investigation and we are conducting a thorough review of all historic transactions related to travel agency use. We also intend to conduct a rigorous review of our compliance procedures in China.
GSK fully respects the laws and regulations in China and expects all staff to abide by them.
We also fully support the efforts of the Chinese authorities in their reforms of the medical sector and stand ready to work with them to make the necessary changes for the benefit of patients in China.
